Teva Pharmaceutical CFO Kalif Eliyahu Sharon Sells $3.63 Million in Shares

Kalif Eliyahu Sharon, the Executive Vice President and Chief Financial Officer of Teva Pharmaceutical Industries Limited, sold 106,563 shares of the company on June 11, 2026. This planned transaction was executed at an average price of $34.10 per share, totaling approximately $3.63 million. Teva's stock was trading at around $33.69 at the time.

Other Institutional Activity in Teva Pharmaceutical

Several institutional investors have also been active in Teva Pharmaceutical. BlackRock, Inc. increased its holdings by 6,833,776 shares, now owning 65,136,464 shares valued at about $1.96 billion. Harel Insurance Investments & Financial Services Ltd. added 1,004,941 shares, reaching a total of 45,956,714 shares worth approximately $1.38 billion. Phoenix Financial Ltd. grew its position by 1,690,283 shares, holding 42,777,414 shares valued at $1.29 billion. WCM Investment Management, LLC significantly boosted its stake by 26,813,522 shares, ending with 40,820,600 shares valued at $1.16 billion.

Teva Pharmaceutical Stock Snapshot

Shares of NYSE:TEVA traded near $33.69. Teva Pharmaceutical has a market cap of $39.2 billion and a P/E ratio of 25.14, with a forward P/E of 10.88. The stock's beta is 0.851, indicating relatively low volatility. Over the past year, the stock has ranged from a low of $14.99 to a high of $37.35. The 50-day moving average is $33.48, while the 200-day moving average is $28.55. The company's current ratio is 1.013, and its debt-to-equity ratio stands at 205.6.

Recent Earnings

Teva Pharmaceutical reported revenue of $17.35 billion, reflecting a growth rate of 2.3%. The net margin was 9.02%, and the return on equity was 21.6%. The company posted an earnings per share of $1.34. The next earnings announcement is scheduled for July 29, 2026.

Insider Buying and Selling at Teva Pharmaceutical Industries Limited

In addition to Kalif Eliyahu Sharon's planned sale, other insiders have been active. On June 5, 2026, Zaks Tal Zvi sold 14,492 shares, while Amir Elstein, Ronit Satchi-Fainaro, Richard Francis (CEO), and Gerald Lieberman each purchased 14,492 shares.

Analysts Set New Price Targets

On May 6, 2026, Barclays maintained its 'buy' rating with a price target of $40. Similarly, on April 30, 2026, JP Morgan and UBS both maintained 'buy' ratings with targets of $40 and $42, respectively. Piper Sandler reiterated a 'buy' rating on April 30, 2026, with a target of $42, and Truist Securities maintained its 'buy' rating with a target of $45 on the same date. The consensus recommendation is a 'strong buy' with an average price target of $40.90 from 10 analysts.

About Teva Pharmaceutical

Teva Pharmaceutical Industries Limited, headquartered in Tel Aviv-Yafo, Israel, is a leading player in the healthcare sector, specifically in the drug manufacturing industry. The company specializes in developing, manufacturing, and distributing generic and specialty medicines, including biopharmaceutical products. Teva operates in the United States, Europe, Israel, and globally, focusing on areas like the central nervous system, respiratory, and oncology. The company employs over 31,000 people and is led by CEO Richard D. Francis.

Bottom Line

Kalif Eliyahu Sharon's recent share sale is part of a planned transaction, reflecting his ongoing role in Teva Pharmaceutical's financial management. Investors watch insider transactions for potential insights into company performance, but such sales are not uncommon and may not indicate future stock performance. Teva remains a significant player in the pharmaceutical industry, with a strong buy recommendation from analysts and a robust market position.